Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy

被引：0
|
作者：
Dellepiane, C. [1 ]
Coco, S. [1 ]
Dal Bello, M. G. [1 ]
Rossi, G. [1 ]
Rijavec, E. [2 ]
Biello, F. [3 ]
Tagliamento, M. [1 ]
Longo, L. [1 ]
Mora, M. [4 ]
Anselmi, G. [4 ]
Alama, A. [1 ]
Bennicelli, E. [1 ]
Grossi, F. [2 ]
Zullo, L. [1 ]
Beshiri, K. [1 ]
Bottini, A. [1 ]
Pronzato, P. [1 ]
Genova, C. [1 ]
机构：
[1] IRCCS Osped Policlin San Martino, Lung Canc Unit, Genoa, Italy
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy
[3] Azienda Osped Univ Maggiore Carita, Med Oncol Unit, Novara, Italy
[4] IRCCS Osped Policlin San Martino, Pathol Unit, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1318P
引用
收藏
页码：S851 / S851
页数：1
相关论文
共 50 条
  • [41] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [42] Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody
    Murakami, Shuji
    Shibaki, Ryota
    Matsumoto, Yuji
    Yoshida, Tatsuya
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Ohe, Yuichiro
    THORACIC CANCER, 2020, 11 (12) : 3585 - 3595
  • [43] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [44] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [45] Prognostic implication of PD-L1 polymorphisms in non-small cell lung cancer treated with radiotherapy
    Kang, Min Kyu
    Lee, Shin Yup
    Choi, Jin Eun
    Do, Sook Kyung
    Cho, Moon-June
    Kim, Jun-Sang
    Park, Jae Yong
    CANCER MEDICINE, 2021, 10 (22): : 8071 - 8078
  • [46] Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
    Puig Sanchez, Francisco Guillermo
    Roman Rodriguez, Lucas
    Barca Hernando, Maria
    Marquez Martin, Eduardo
    Romero Romero, Beatriz
    Martin Juan, Jose
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [47] Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patients
    Krupa, R.
    Lu, D.
    Harvey, M.
    Louw, J.
    Jendrisak, A.
    Marrinucci, D.
    Dittamore, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 45 - 45
  • [48] Longitudinal evaluation of PD-L1 expression on circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab
    Ikeda, Mio
    Koh, Yasuhiro
    Teraoka, Shunsuke
    Sato, Koichi
    Tokudome, Nahomi
    Hayata, Atsushi
    Akamatsu, Hiroaki
    Ozawa, Yuichi
    Akamatsu, Keiichiro
    Endo, Katsuya
    Higuchi, Masayuki
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 83 - 83
  • [49] Longitudinal investigation of PD-L1 expression on circulating tumor cells (CTCs) in non-small cell lung cancer (NSCLC) patients treated with nivolumab
    Koh, Yasuhiro
    Ikeda, Mio
    Teraoka, Shunsuke
    Sato, Koichi
    Tokudome, Nahomi
    Hayata, Atsushi
    Akamatsu, Hiroaki
    Ozawa, Yuichi
    Akamatsu, Keiichiro
    Endo, Katsuya
    Higuchi, Masayuki
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    CANCER RESEARCH, 2020, 80 (16)
  • [50] PD-L1 status in patients of the Moscow region with non-small cell lung cancer
    Byakhova, M.
    Zavalishina, L.
    Andreeva, Y.
    Tsimafeyeu, I.
    Savelov, N.
    Tjulandin, S.
    Frank, G.
    VIRCHOWS ARCHIV, 2020, 477 : S364 - S364
12345